An Overview of Signs and Symptoms to Determine Coronavirus and Omicron Patients in Primary Care and Hospitals

Keywords: Coronavirus disease 19, omicron, health care, signs, symptoms

Abstract

Coronaviruses, a type of virus family, cause severe respiratory diseases in people. The coronavirus is most frequently linked to the common cold, but in persons with SARS (severe acute respiratory syndrome) virus infection, it can also lead to serious respiratory sickness. The spread of the coronavirus is by having direct contact with infected saliva, mucus, or blood. Infected surfaces, such as those in hospitals or other healthcare facilities, can potentially spread the infection when touched. Now spreading globally is the Omicron version of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). According to preliminary studies, the Omicron variant of SARS-CoV-2 has a higher probability of re-infection. To recognize COVID-19 as well as omicron people in hospitals and primary health care, this review study focuses on the symptoms and indications. The data was collected and analyzed from more than one hundred high-impact original research papers to conclude their results and make a comparison between methods and findings.

Downloads

Download data is not yet available.

Author Biographies

Ali M.Hussein, Department of Biomedical Sciences, College of Science, Cihan University-Erbil, Kurdistan Region, Iraq

Ali M. Hussein is a Lecturer at the Department of Biomedical Sciences, College of Science, Cihan University-Erbil. He got the Ph.D. Microbiology. His research interests are in Pathogenic Bacteria, Molecular Microbiology, and Biotechnology. Dr. Ali is a member of the Microbiology Society journals.

Hawry A. Majeed, Department of Biomedical Sciences, College of Science, Cihan University-Erbil, Kurdistan Region, Iraq

Hawry Amanj Majeed is a Student at the Department of Biomedical Sciences, College of Science, Cihan University-Erbil, Kurdistan Region, Iraq.

Naz R. Majeed, Department of Biomedical Sciences, College of Science, Cihan University-Erbil, Kurdistan Region, Iraq

Naz Rebaz Majeed is a Graduate of the Department of Biomedical Sciences, College of Science, Cihan University-Erbil, Kurdistan Region, Iraq. She got a B.Sc. degree in Biomedical Sciences.

Nza H.M. Ali, Department of Biomedical Sciences, College of Science, Cihan University-Erbil, Kurdistan Region, Iraq

Nza Hamid Mohammed Ali is a Lab Assistant at the Department of Biomedical Sciences, College of Science, Cihan University-Erbil, Kurdistan Region, Iraq. She got a B.Sc. degree from Hawler Medical University / College of Health Sciences / Department of Medical Microbiology.

Dashne A. Saeed, Department of General Education, College of Education, Cihan University-Erbil, Kurdistan Region, Iraq

 Dashne Abdullah Saeed is an Assistant Lecturer with an M.A. degree in Teaching Methods in General Science. She got a B.Sc. degree from Salahaddin University, College of Basic Education, Department of General Science. Currently, she is teaching in the Department of General Education at Cihan University-Erbil, Kurdistan Region, Iraq. Her research interest includes teaching methods, learning styles, and Psychology.

Narmin A. Ali, Department of Community Health Nursing, College of Health Technology, Cihan University-Erbil, Kurdistan Region, Iraq

Narmin Abubaker Ali is an Assistant Lecturer at the Department of Community Health Nursing, College of Health Technology, Cihan University-Erbil, Kurdistan Region, Iraq.

References

F. Abdullah, J. Myers, D. Basu, G. Tintinger, V. Ueckermann, M. Mathebula, R. Ramlall, S. Spoor, T. de Villiers, Z. Van der Walt, J. Cloete, P. Soma-Pillay, P. Rheeder, F. Paruk, A. Engelbrecht, V. Lalloo, M. Myburg, J. Kistan, W. van Hougenhouck-Tulleken, M. T. Boswell, G. Gray, R. Welch, L. Blumberg and W. Jassat. Decreased severity of disease during the first global Omicron variant covid-19 outbreak in a large hospital in tshwane, South Africa. International Journal of Infectious Diseases, vol. 116, pp. 38-42, 2022.

S. Evans, D. Holt, C. Weil-Olivier, G. Finnegan and V. Usonis. Building population and health system resilience: Using lessons learned during the COVID pandemic to implement life-course immunisation policy. Vaccine, vol. 40, no. 26, pp. 3511-3513, 2022.

N. Van Goethem, P. Y. J. Chung, M. Meurisse, M. Vandromme, L. De Mot, R. Brondeel, V. Stouten, S. Klamer, L. Cuypers, T. Braeye, L. Catteau, L. Nevejan, J. A. F. van Loenhout and K. Blot. Clinical severity of SARS-CoV-2 Omicron variant compared with delta among hospitalized COVID-19 patients in Belgium during Autumn and Winter season 2021-2022. Viruses, vol. 14, no. 6, p. 1297, 2022.

V. Jordan. Coronavirus (COVID-19): Using signs and symptoms to diagnose COVID-19 in primary care. Journal of Primary Health Care, vol. 14, no. 2, pp. 187-188, 2022.

Y. Kawano, N. J. Patel, X. Wang, C. E. Cook, K. M. Vanni, E. N. Kowalski, E. P. Banasiak, G. Qian, M. DiIorio, T. Y. T. Hsu, M. E. Weinblatt, D. J. Todd, Z. S. Wallace and J. A. Sparks. Temporal trends in COVID-19 outcomes among patients with systemic autoimmune rheumatic diseases: From the first wave through the initial Omicron wave. Annals of the Rheumatic Diseases, vol. 81, no. 12, pp. 1742-1749, 2022.

S. K. Berg, P. Palm, U. Nygaard, H. Bundgaard, M. N. S. Petersen, S. Rosenkilde, A. B. Thorsted, A. K. Ersbøll, L. C. Thygesen, S. D. Nielsen and A. V. Christensen. Long COVID symptoms in SARS-CoV-2-positive children aged 0-14 years and matched controls in Denmark (LongCOVIDKidsDK): A national, crosssectional study. The Lancet Child and Adolescent Health, vol. 6, no. 9, pp. 614-623, 2022.

T. K. Burki. Omicron variant and booster COVID-19 vaccines. The Lancet Respiratory Medicine, vol. 10, no. 2, p. e17, 2022.

Y. Du, L. Chen and Y. Shi. Booster COVID-19 vaccination against the SARS-CoV-2 Omicron variant: A systematic review. Human Vaccines and Immunotherapeutics, vol. 18, no. 5, p. 2062983, 2022.

C. A. Taylor, M. Whitaker, O. Anglin, J. Milucky, K. Patel, H. Pham, S. J. Chai, N. B. Alden, K. Yousey-Hindes, E. J. Anderson, K. Teno, L. Reeg, K. Como-Sabetti, M. Bleecker, G. Barney, N. M. Bennett, L. M. Billing, M. Sutton, H. K. Talbot, K. McCaffrey, F. P. Havers and COVID-NET Surveillance Team. COVID-19-associated hospitalizations among adults during SARS-CoV-2 delta and Omicron variant predominance, by race/ethnicity and vaccination status-COVID-NET, 14 states, July 2021-January 2022. Morbidity and Mortality Weekly Report, vol. 71, no. 12, pp. 466-473, 2022.

K. Adams, J. P. Rhoads, D. Surie, M. Gaglani, A. A. Ginde, T. McNeal, H. K. Talbot, J. D. Casey, A. Zepeski, N. I. Shapiro, K. W. Gibbs, D. C. Files, D. N. Hager,… and A. E. Forsch. Vaccine effectiveness of primary series and booster doses against covid-19 associated hospital admissions in the United States: Living test negative design study. BMJ, vol. 379, p. e072065, 2022.

M. Antonelli, J. C. Pujol, T. D. Spector, S. Ourselin and C. J. Steves. Risk of long COVID associated with delta versus Omicron variants of SARS-CoV-2. The Lancet, vol. 399, no. 10343, pp. 2263-2264, 2022.

S. Chenchula, P. Karunakaran, S. Sharma and M. Chavan. Current evidence on efficacy of COVID-19 booster dose vaccination against the Omicron variant: A systematic review. Journal of Medical Virology, vol. 94, no. 7, pp. 2969-2976, 2022.

D. Eggink, S. P. Andeweg, H. Vennema, N. van Maarseveen, K. Vermaas, B. Vlaemynck, R. Schepers, A. B. van Gageldonk- Lafeber, S. van den Hof, C. B. Reusken and M. Knol. Increased risk of infection with SARS-CoV-2 Omicron BA.1 compared with Delta in vaccinated and previously infected individuals, the Netherlands, 22 November 2021 to 19 January 2022. Eurosurveillance, vol. 27, no. 4, p. 2101196, 2022.

D. Wu, Y. Ye, L. Tang, A. B. Wang, R. Zhang, Z. H. Qian, F. Z. Wang, H. Zheng, C. Huang, X. Y. Lv, H. F. Wang, Y. Y. Zhang, J. J. Pan, Y. F. Li,… and M. X. Lu. A case-case study on the effect of primary and booster immunization with China-produced COVID-19 vaccines on prevention of pneumonia and viral load among vaccinated persons infected by Delta and Omicron variants. Emerging Microbes and Infections, vol. 11, no. 1, pp. 1950-1958, 2022.

S. Swed, F. Kashkash, S. Shoib, N. Shaheen, M. N. Nasif,F. Abdullah, J. Myers, D. Basu, G. Tintinger, V. Ueckermann, M. Mathebula, R. Ramlall, S. Spoor, T. de Villiers, Z. Van der Walt, J. Cloete, P. Soma-Pillay, P. Rheeder, F. Paruk, A. Engelbrecht, V. Lalloo, M. Myburg, J. Kistan, W. van Hougenhouck-Tulleken, M. T. Boswell, G. Gray, R. Welch, L. Blumberg and W. Jassat. Decreased severity of disease during the first global Omicron variant covid-19 outbreak in a large hospital in tshwane, South Africa. International Journal of Infectious Diseases, vol. 116, pp. 38-42, 2022.

S. Evans, D. Holt, C. Weil-Olivier, G. Finnegan and V. Usonis. Building population and health system resilience: Using lessons learned during the COVID pandemic to implement life-course immunisation policy. Vaccine, vol. 40, no. 26, pp. 3511-3513, 2022.

N. Van Goethem, P. Y. J. Chung, M. Meurisse, M. Vandromme, L. De Mot, R. Brondeel, V. Stouten, S. Klamer, L. Cuypers, T. Braeye, L. Catteau, L. Nevejan, J. A. F. van Loenhout and K. Blot. Clinical severity of SARS-CoV-2 Omicron variant compared with delta among hospitalized COVID-19 patients in Belgium during Autumn and Winter season 2021-2022. Viruses, vol. 14, no. 6, p. 1297, 2022.

V. Jordan. Coronavirus (COVID-19): Using signs and symptoms to diagnose COVID-19 in primary care. Journal of Primary Health Care, vol. 14, no. 2, pp. 187-188, 2022.

Y. Kawano, N. J. Patel, X. Wang, C. E. Cook, K. M. Vanni, E. N. Kowalski, E. P. Banasiak, G. Qian, M. DiIorio, T. Y. T. Hsu, M. E. Weinblatt, D. J. Todd, Z. S. Wallace and J. A. Sparks. Temporal trends in COVID-19 outcomes among patients with systemic autoimmune rheumatic diseases: From the first wave through the initial Omicron wave. Annals of the Rheumatic Diseases, vol. 81, no. 12, pp. 1742-1749, 2022.

S. K. Berg, P. Palm, U. Nygaard, H. Bundgaard, M. N. S. Petersen, S. Rosenkilde, A. B. Thorsted, A. K. Ersbøll, L. C. Thygesen, S. D. Nielsen and A. V. Christensen. Long COVID symptoms in SARS-CoV-2-positive children aged 0-14 years and matched controls in Denmark (LongCOVIDKidsDK): A national, crosssectional study. The Lancet Child and Adolescent Health, vol. 6, no. 9, pp. 614-623, 2022.

T. K. Burki. Omicron variant and booster COVID-19 vaccines. The Lancet Respiratory Medicine, vol. 10, no. 2, p. e17, 2022. 8. Y. Du, L. Chen and Y. Shi. Booster COVID-19 vaccination against the SARS-CoV-2 Omicron variant: A systematic review. Human Vaccines and Immunotherapeutics, vol. 18, no. 5, p. 2062983, 2022.

C. A. Taylor, M. Whitaker, O. Anglin, J. Milucky, K. Patel, H. Pham, S. J. Chai, N. B. Alden, K. Yousey-Hindes, E. J. Anderson, K. Teno, L. Reeg, K. Como-Sabetti, M. Bleecker, G. Barney, N. M. Bennett, L. M. Billing, M. Sutton, H. K. Talbot, K. McCaffrey, F. P. Havers and COVID-NET Surveillance Team. COVID-19-associated hospitalizations among adults during SARS-CoV-2 delta and Omicron variant predominance, by race/ethnicity and vaccination status-COVID-NET, 14 states, July 2021-January 2022. Morbidity and Mortality Weekly Report, vol. 71, no. 12, pp. 466-473, 2022.

K. Adams, J. P. Rhoads, D. Surie, M. Gaglani, A. A. Ginde, T. McNeal, H. K. Talbot, J. D. Casey, A. Zepeski, N. I. Shapiro, K. W. Gibbs, D. C. Files, D. N. Hager,… and A. E. Forsch. Vaccine effectiveness of primary series and booster doses against covid-19 associated hospital admissions in the United States: Living test negative design study. BMJ, vol. 379, p. e072065, 2022.

M. Antonelli, J. C. Pujol, T. D. Spector, S. Ourselin and C. J. Steves. Risk of long COVID associated with delta versus Omicron variants of SARS-CoV-2. The Lancet, vol. 399, no. 10343, pp. 2263-2264, 2022.

S. Chenchula, P. Karunakaran, S. Sharma and M. Chavan. Current evidence on efficacy of COVID-19 booster dose vaccination against the Omicron variant: A systematic review. Journal of Medical Virology, vol. 94, no. 7, pp. 2969-2976, 2022.

D. Eggink, S. P. Andeweg, H. Vennema, N. van Maarseveen, K. Vermaas, B. Vlaemynck, R. Schepers, A. B. van Gageldonk- Lafeber, S. van den Hof, C. B. Reusken and M. Knol. Increased risk of infection with SARS-CoV-2 Omicron BA.1 compared with Delta in vaccinated and previously infected individuals, the Netherlands, 22 November 2021 to 19 January 2022. Eurosurveillance, vol. 27, no. 4, p. 2101196, 2022.

D. Wu, Y. Ye, L. Tang, A. B. Wang, R. Zhang, Z. H. Qian, F. Z. Wang, H. Zheng, C. Huang, X. Y. Lv, H. F. Wang, Y. Y. Zhang, J. J. Pan, Y. F. Li,… and M. X. Lu. A case-case study on the effect of primary and booster immunization with China-produced COVID-19 vaccines on prevention of pneumonia and viral load among vaccinated persons infected by Delta and Omicron variants. Emerging Microbes and Infections, vol. 11, no. 1, pp. 1950-1958, 2022.

S. Swed, F. Kashkash, S. Shoib, N. Shaheen, M. N. Nasif,F. Abdullah, J. Myers, D. Basu, G. Tintinger, V. Ueckermann, M. Mathebula, R. Ramlall, S. Spoor, T. de Villiers, Z. Van der Walt, J. Cloete, P. Soma-Pillay, P. Rheeder, F. Paruk, A. Engelbrecht, V. Lalloo, M. Myburg, J. Kistan, W. van Hougenhouck-Tulleken, M. T. Boswell, G. Gray, R. Welch, L. Blumberg and W. Jassat. Decreased severity of disease during the first global Omicron variant covid-19 outbreak in a large hospital in tshwane, South Africa. International Journal of Infectious Diseases, vol. 116, pp. 38-42, 2022.

F. B. Mayr, V. B. Talisa, A. D. Castro, O. S. Shaikh, S. B. Omer and A. A. Butt. COVID-19 disease severity in US veterans infected during Omicron and Delta variant predominant periods. Nature Communications, vol. 13, no. 1, p. 3647, 2022.

X. Chen, X. Yan, K. Sun, N. Zheng, R. Sun, J. Zhou, X. Deng, T. Zhuang, J. Cai, J. Zhang, M. Ajelli and H. Yu. Estimation of disease burden and clinical severity of COVID-19 caused by Omicron BA.2 in Shanghai, February-June 2022. Emerging Microbes and Infections, vol. 11, no. 1, pp. 2800-2807, 2022.

A. Dinh, L. Dahmane, M. Dahoumane, X. Masingue, P. Jourdain and F. X. Lescure. Impact of Omicron surge in community setting in greater Paris area. Clinical Microbiology and Infection, vol. 28, no. 6, pp. 897-899, 2022.

J. A. Otter, W. Newsholme, L. B. Snell, B. Merrick, N. Okeke D. J. F. Mack, A. S. Breathnach and N. M. Price. Evaluation of clinical harm associated with Omicron hospital-onset COVID-19 infection. Journal of Infection, vol. 86, no. 1, pp. 66-117, 2023.

M. G. Chibwana, H. W. Thole, C. Anscombe, P. M. Ashton, E. Green, K. G. Barnes, J. Cornick, A. Turner, D. Witte, S. Nthala, C. Thom, F. Kanyandula, A. Ainani, N. Mtike, H. Tambala,… and V. N’goma. Differential symptoms among COVID-19 outpatients before and during periods of SARS-CoV-2 Omicron variant dominance in Blantyre, Malawi: A prospective observational study. MedRxiv, 2022. https://doi.org/10.1101/2022.07.15.22277665

M. H. Ebell, R. Hamadani and A. Kieber-Emmons. Development and validation of simple risk scores to predict hospitalization in outpatients with COVID-19 including the Omicron variant. The Journal of the American Board of Family Medicine, vol. 35, no. 6, pp. 1058-1064, 2022.

S. K. Greene, A. Levin-Rector, E. Luoma, H. Amin, E. McGibbon, R. W. Mathes and S. D. Ahuja. Assessment of COVID-19 hospitalization risk during SARS-CoV-2 Omicron relative to Delta variant predominance, New York City, August 2021-January 2022.

Medrxiv, 2022. https://doi.org/10.1101/2022.07.15.22276814 23. G. Lu, Y. Zhang, H. Zhang, J. Ai, L. He, X. Yuan, S. Bao, X. Chen, H. Wang, J. Cai, S. Wang, W. Zhang and J. Xu. Geriatric risk and protective factors for serious COVID-19 outcomes among older adults in Shanghai Omicron wave. Emerging Microbes and Infections, vol. 11, no. 1, pp. 2045-2054, 2022.

E. K. Accorsi, A. Britton, K. E. Fleming-Dutra, Z. R. Smith, N. Shang, G. Derado, J. Miller, S. J. Schrag and J. R. Verani. Association between 3 doses of mRNA COVID-19 vaccine and symptomatic infection caused by the SARS-CoV-2 Omicron and Delta variants. JAMA, vol. 327, no. 7, pp. 639-651, 2022.

R. Cohen, A. Rybak, N. Ouldali, F. Angoulvant, S. Béchet, V. Gajdos, I. Hau, A. Sellam, I. E. A. El Ghomari, F. Elmerich, C. Batard, A. Auvrignon, E. Grimprel, M. Favier, C. Jung and C. Levy. From the original SARS-CoV-2 strain to the Omicron variant: Predictors of COVID-19 in ambulatory symptomatic children. Infectious Diseases Now, vol. 52, no. 8, pp. 432-440, 2022.

H. N. Altarawneh, H. Chemaitelly, H. H. Ayoub, P. Tang, M. R. Hasan, H. M. Yassine, H. A. Al-Khatib, M. K. Smatti, P. Coyle, Z. Al-Kanaani, E. Al-Kuwari, A. Jeremijenko, A. H. Kaleeckal, A. N. Latif and R. M. Shaik. Effect of prior infection, vaccination, and hybrid immunity against symptomatic BA.1 and BA.2 Omicron infections and severe COVID-19 in Qatar. MedRxiv, 2022. https://doi.org/10.1101/2022.03.22.22272745

J. Cloete, A. Kruger, M. Masha, N. M. du Plessis, D. Mawela, M. Tshukudu, T. Manyane, L. Komane, M. Venter, W. Jassat, A. Goga and U. Feucht. Rapid rise in paediatric COVID-19 hospitalisations during the early stages of the Omicron wave, Tshwane District, South Africa. Medrxiv, 2021. https://doi.org/10.1101/2021.12.21.21268108

C. D. De Luca, E. Esposito, L. Cristiani, E. Mancino, R. Nenna, E. Cortis and F. Midulla. Covid-19 in children: A brief overview after three months experience. Paediatric Respiratory Reviews, vol. 35, pp. 9-14, 2020.

J. Cloete, A. Kruger, M. Masha, N. M. du Plessis, D. Mawela, M. Tshukudu, T. Manyane, L. Komane, M. Venter, W. Jassat, A. Goga and U. Feucht. Paediatric hospitalisations due to COVID-19 during the first SARS-CoV-2 Omicron (B.1.1.529) variant wave in South Africa: A multicentre observational study. The Lancet Child and Adolescent Health, vol. 6, no. 5, pp. 294-302, 2022.

F. Grabowski, M. Kochańczyk and T. Lipniacki. Omicron strain spreads with the doubling time of 3.2-3.6 days in South Africa province of Gauteng that achieved herd immunity to Delta variant MedRxiv, 2021. https://doi.org/10.1101/2021.12.08.21267494

A. F. Voor In ‘t Holt, C. P. Haanappel, J. Rahamat-Langendoen, R. Molenkamp, E. van Nood, L. M. van den Toorn, R. P. Peeters, A. M. C. van Rossum and J. A. Severin. Admissions to a large tertiary care hospital and Omicron BA.1 and BA.2 SARS-CoV-2 polymerase chain reaction positivity: Primary, contributing, or incidental COVID-19. International Journal of Infectious Diseases, vol. 122, pp. 665-668, 2022.

R. Grewal, S. A. Kitchen, L. Nguyen, S. A. Buchan, S. E. Wilson, A. P. Costa and J. C. Kwong. Effectiveness of a fourth dose of covid-19 mRNA vaccine against the Omicron variant among long term care residents in Ontario, Canada: Test negative design study. BMJ, vol. 378, p. e071502, 2022.

J. T. Solera, B. G. Árbol, A. Alshahrani, I. Bahinskaya, N. Marks, A. Humar and D. Kumar. Impact of vaccination and early monoclonal antibody therapy on coronavirus disease 2019 outcomes in organ transplant recipients during the Omicron wave. Clinical Infectious Diseases, vol. 75, no. 12, pp. 2193-2200, 2022.

M. E. Modes, M. P. Directo, M. Melgar, L. R. Johnson, H. Yang, P. Chaudhary, S. Bartolini, N. Kho, P. W. Noble, S. Isonaka and P. Chen. Clinical characteristics and outcomes among adults hospitalized with laboratory-confirmed SARS-CoV-2 infection during periods of B.1.617.2 (Delta) and B.1.1.529 (Omicron) variant predominance-one hospital, California, July 15-September 23, 2021, and December 21, 2021-January 27, 2022. Morbidity and Mortality Weekly Report, vol. 71, no. 6, pp. 217-223, 2022.

D. R. Feikin, L. J. Abu-Raddad, N. Andrews, M. A. Davies, M. M. Higdon, W. A. Orenstein and M. K. Patel. Assessing vaccine effectiveness against severe COVID-19 disease caused by Omicron variant. Report from a meeting of the World Health Organization. Vaccine, vol. 40, no. 26, pp. 3516-3527, 2022.

E. Schuit, R. P. Venekamp, L. Hooft, I. K. Veldhuijzen, W. van den Bijllaardt, S. D. Pas, V. F. Zwart, E. B. Lodder, M. Hellwich, M. Koppelman, R. Molenkamp, C. J. H. Wijers, I. H. Vroom, L. C. Smeets, C. R. S. Nagel-Imming, W. G. H. Han, S. van den Hof, J. A. J. W. Kluytmans, J. H. H. M. van de Wijgert and K. G. M. Moons. Diagnostic accuracy of covid-19 rapid antigen tests with unsupervised self-sampling in people with symptoms in the Omicron period: Cross sectional study. BMJ, vol. 378, p. e071215, 2022.

M. Risk, S. S. Hayek, E. Schiopu, L. Yuan, C. Shen, X. Shi, G. Freed and L. Zhao. COVID-19 vaccine effectiveness against Omicron (B.1.1.529) variant infection and hospitalisation in patients taking immunosuppressive medications: A retrospective cohort study. The Lancet Rheumatology, vol. 4, no. 11, pp. e775-e784, 2022.

I. L. Ward, C. Bermingham, D. Ayoubkhani, O. J. Gethings, K. B. Pouwels, T. Yates, K. Khunti, J. Hippisley-Cox, A. Banerjee, A. S. Walker and V. Nafilyan. Risk of covid-19 related deaths for SARSCoV- 2 Omicron (B.1.1.529) compared with Delta (B.1.617.2): Retrospective cohort study. BMJ, vol. 378, p. e070695, 2022.

Published
2024-02-05
How to Cite
1.
M.Hussein A, Majeed H, Majeed N, Ali N, Saeed D, Ali N. An Overview of Signs and Symptoms to Determine Coronavirus and Omicron Patients in Primary Care and Hospitals. cuesj [Internet]. 5Feb.2024 [cited 24Apr.2024];8(1):8-7. Available from: https://journals.cihanuniversity.edu.iq/index.php/cuesj/article/view/1047
Section
Research Article